Avinger (AVGR) Misses Q3 EPS by 21c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- Wall St subdued as markets pause after S&P record high; data, Mideast in focus
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Avinger, Inc. Announces Third Quarter 2015 Results
November 5, 2015 4:09 PM ESTReceived FDA Clearance for Pantheris
Accelerated Expansion of Installed Base of Lumivascular Platform
REDWOOD CITY, Calif., Nov. 5, 2015 (GLOBE NEWSWIRE) -- Avinger, Inc., (NASDAQ: AVGR) a developer and manufacturer of image-guided, catheter-based systems for the treatment of peripheral arterial disease (PAD) and pioneer of the lumivascular approach to treating vascular disease, today reported results for the third quarter ended September 30, 2015.
Recent Highlights
Received 510(k) clearance from the United States Food and Drug Administration (FDA) to commence U.S. commercialization of Pantheris, the first-ever image-guided atherectomy device using... MoreAvinger, Inc. to Present at Upcoming Investor Conferences
November 3, 2015 4:05 PM ESTREDWOOD CITY, Calif., Nov. 3, 2015 (GLOBE NEWSWIRE) -- Avinger, Inc. (NASDAQ: AVGR) a developer and manufacturer of image-guided, catheter-based systems for the treatment of peripheral arterial disease (PAD) and pioneer of the lumivascular approach to treating vascular disease, today announced the Company will be participating in two upcoming investor conferences.
Avinger's management is scheduled to present at the Stephens Fall Investment Conference in New York City, NY on... More
